New Stavanger University Hospital - IO-9844 Colour instrument PD-L1 - IHC 22C3

Description

Stavanger Hospital Trust, c/o New SUS intends to enter into a contract with Agilent DGG Norge AS for the delivery of instruments for immunohistochemistry/colour instrument PD-L1 IHC 22C3 Pembrolizumab, including instrument-specific consumables for the new Stavanger University Hospital. Lot 1: Stavanger Hospital Trust, c/o New SUS intends to enter into a contract with Agilent DGG Norge AS for the delivery of instruments for immunohistochemistry/colour instrument PD-L1 IHC 22C3 Pembrolizumab, including instrument-specific consumables for the new Stavanger University Hospital. In accordance with the national guidelines, national action programme with guidelines for diagnostics, treatment, and follow-up of patients with breast cancer, the contracting authority understands that only Agilent can deliver instrument PD-L1 IHC 22C3 Pembrolizumab in accordance with the guidelines (Dako Omnis). The contracting authority has therefore obtained tender information directly from Agilent, and intends to enter into a contract with them after the publication of this voluntary ex-ante transparency notice, provided that no objections are received within 10 days of the notice. Suppliers that have questions or input are encouraged to contact us well before the deadline.